Published in Trends Immunol on October 07, 2005
A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology (2012) 2.46
Mast cells and inflammation. Biochim Biophys Acta (2010) 1.91
Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci (2012) 1.67
Stress exacerbates neuropathic pain via glucocorticoid and NMDA receptor activation. Brain Behav Immun (2009) 1.18
Autonomic dysfunction in Guillain-Barré syndrome and multiple sclerosis. J Neurol (2007) 1.04
Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis. J Neurol (2006) 1.03
Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry (2010) 1.03
Gender and sex hormones in multiple sclerosis pathology and therapy. Front Biosci (Landmark Ed) (2009) 0.95
Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation. Nat Immunol (2015) 0.88
Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression. Dialogues Clin Neurosci (2007) 0.88
The effect of repeated restraint stress in pain-related behavior induced by nucleus pulposus applied on the nerve root in rats. Eur Spine J (2011) 0.84
Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol (2013) 0.83
Stress and multiple sclerosis. J Neurol (2007) 0.83
FGF-2 released from degenerating neurons exerts microglial-induced neuroprotection via FGFR3-ERK signaling pathway. J Neuroinflammation (2014) 0.82
Stress and the risk of multiple sclerosis. Neurology (2011) 0.81
Perceived stress in multiple sclerosis: the potential role of mindfulness in health and well-being. J Evid Based Complementary Altern Med (2014) 0.81
Pregnancy and multiple sclerosis: from molecular mechanisms to clinical application. Semin Immunopathol (2016) 0.81
Posttraumatic stress disorder-like induction elevates β-amyloid levels, which directly activates corticotropin-releasing factor neurons to exacerbate stress responses. J Neurosci (2015) 0.79
Stress as provoking factor for the first and repeated multiple sclerosis seizures. Mater Sociomed (2012) 0.76
Stress-induced brain activity, brain atrophy, and clinical disability in multiple sclerosis. Proc Natl Acad Sci U S A (2016) 0.75
Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress. Health Psychol Open (2015) 0.75
Mobile health technology evaluation: the mHealth evidence workshop. Am J Prev Med (2013) 3.90
Harnessing context sensing to develop a mobile intervention for depression. J Med Internet Res (2011) 3.44
Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology (2005) 3.28
Neuroendocrine regulation of immunity. Annu Rev Immunol (2001) 3.11
Teamwork culture and patient satisfaction in hospitals. Med Care (2004) 2.05
Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst (2012) 1.94
Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med (2011) 1.93
Effects of Hatha yoga and African dance on perceived stress, affect, and salivary cortisol. Ann Behav Med (2004) 1.87
Caregiving burden, stress, and health effects among family caregivers of adult cancer patients. JAMA (2012) 1.85
A meta-analysis of cortisol response to challenge in human aging: importance of gender. Psychoneuroendocrinology (2005) 1.79
Diurnal cortisol variations and symptoms in patients with interstitial cystitis. J Urol (2002) 1.73
C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci U S A (2012) 1.73
Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci (2012) 1.67
[Criteria for evidence-based patient information]. Z Arztl Fortbild Qualitatssich (2005) 1.64
Development and usability testing of FOCUS: a smartphone system for self-management of schizophrenia. Psychiatr Rehabil J (2013) 1.63
Stress facilitates consolidation of verbal memory for a film but does not affect retrieval. Behav Neurosci (2006) 1.62
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry (2011) 1.53
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Mobile Phone Sensor Correlates of Depressive Symptom Severity in Daily-Life Behavior: An Exploratory Study. J Med Internet Res (2015) 1.50
Role of the hypothalamic-pituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products. J Endocrinol (2004) 1.47
Self-guided psychological treatment for depressive symptoms: a meta-analysis. PLoS One (2011) 1.47
Nurse practitioner and physician assistant scope of practice in 118 acute care hospitals. J Hosp Med (2014) 1.41
Participation preferences of patients with acute and chronic conditions. Health Expect (2007) 1.40
Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol (2007) 1.40
Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther (2003) 1.40
Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol (2003) 1.39
Low bone mass in premenopausal women with depression. Arch Intern Med (2007) 1.38
The Lourdes medical cures revisited. J Hist Med Allied Sci (2012) 1.38
Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol (2008) 1.37
Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp Neurol (2010) 1.36
Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol (2007) 1.36
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol (2012) 1.34
The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med (2005) 1.34
Assessing an organizational culture instrument based on the Competing Values Framework: exploratory and confirmatory factor analyses. Implement Sci (2007) 1.32
Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci (2004) 1.28
Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study. Biol Psychiatry (2008) 1.26
Strategies for mHealth research: lessons from 3 mobile intervention studies. Adm Policy Ment Health (2015) 1.25
Progesterone inhibits mature rat dendritic cells in a receptor-mediated fashion. Int Immunol (2007) 1.24
Longterm quiescent cells in the aged human subventricular neurogenic system specifically express GFAP-delta. Aging Cell (2010) 1.22
Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem (2010) 1.22
What are successful recruitment and retention strategies for underserved populations? Examining physical activity interventions in primary care and community settings. Transl Behav Med (2011) 1.20
Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Mult Scler (2003) 1.19
Neuroendocrine factors alter host defense by modulating immune function. Cell Immunol (2008) 1.19
Anthrax lethal factor represses glucocorticoid and progesterone receptor activity. Proc Natl Acad Sci U S A (2003) 1.16
Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol (2009) 1.16
Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res (2005) 1.14
Project onward: an innovative e-health intervention for cancer survivors. Psychooncology (2012) 1.14
Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice. Neurobiol Aging (2013) 1.12
Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics. Ann N Y Acad Sci (2009) 1.12
Patients' and observers' perceptions of involvement differ. Validation study on inter-relating measures for shared decision making. PLoS One (2011) 1.11
Evidence-based patient information about treatment of multiple sclerosis--a phase one study on comprehension and emotional responses. Patient Educ Couns (2005) 1.10
The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease. J Leukoc Biol (2008) 1.09
A computational future for preventing HIV in minority communities: how advanced technology can improve implementation of effective programs. J Acquir Immune Defic Syndr (2013) 1.09
Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain (2009) 1.09
Neural-immune interactions in health and disease. Ann N Y Acad Sci (2002) 1.09
Internet intervention for increasing physical activity in persons with multiple sclerosis. Mult Scler (2010) 1.08
Phenotyping primary human microglia: tight regulation of LPS responsiveness. Glia (2012) 1.06
Endocrine perturbation increases susceptibility of mice to anthrax lethal toxin. Infect Immun (2005) 1.06
Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 1.05
Measurement of cytokines in sweat patches and plasma in healthy women: validation in a controlled study. J Immunol Methods (2006) 1.04
Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation. J Innate Immun (2009) 1.03
Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2013) 1.02
Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology (2010) 1.02
Diminished aromatase immunoreactivity in the hypothalamus, but not in the basal forebrain nuclei in Alzheimer's disease. Neurobiol Aging (2005) 1.02
Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol (2012) 1.02
Neural aspects of immunomodulation: focus on the vagus nerve. Brain Behav Immun (2010) 1.02
Modafinil effects in multiple sclerosis patients with fatigue. J Neurol (2009) 1.01
Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder. J Psychiatr Res (2010) 0.99
Team effectiveness and organizational context in the implementation of a clinical innovation. Qual Manag Health Care (2009) 0.98
Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J Neuropathol Exp Neurol (2013) 0.97
Brain banking for neurological disorders. Lancet Neurol (2013) 0.97
MAPPIN'SDM--the multifocal approach to sharing in shared decision making. PLoS One (2012) 0.97
Neuroendocrine and immune contributors to fatigue. PM R (2010) 0.97
The microtubule regulator stathmin is an endogenous protein agonist for TLR3. J Immunol (2010) 0.97
Purple: a modular system for developing and deploying behavioral intervention technologies. J Med Internet Res (2014) 0.97
mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge. JMIR Ment Health (2016) 0.96
Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry (2014) 0.95
Grounded theory of barriers and facilitators to mandated implementation of mental health care in the primary care setting. Depress Res Treat (2012) 0.95
Spleen vagal denervation inhibits the production of antibodies to circulating antigens. PLoS One (2008) 0.94
Alliance in two telephone-administered treatments: relationship with depression and health outcomes. J Consult Clin Psychol (2007) 0.94
Development of the brief inventory of perceived stress. J Clin Psychol (2012) 0.94
Information provision for people with multiple sclerosis. Cochrane Database Syst Rev (2014) 0.93
Sustainability of quality improvement following removal of pay-for-performance incentives. J Gen Intern Med (2013) 0.93
Internet-delivered behavioral intervention to increase physical activity in persons with multiple sclerosis: sustainability and secondary outcomes. Psychol Health Med (2012) 0.93
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord (2012) 0.93
Inflammatory genes and neural activity: involvement of immune genes in synaptic function and behavior. Front Biosci (2005) 0.92
Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol (2005) 0.92
Physical activity, disability, and mood in the early stage of multiple sclerosis. Disabil Health J (2009) 0.92
Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance. Neuroimmunomodulation (2008) 0.92
Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. J Rheumatol (2002) 0.92
Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments. PLoS One (2013) 0.92
Depressive syndromes in neurological disorders. Eur Arch Psychiatry Clin Neurosci (2013) 0.91
Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced IL-6 production. J Neuroimmunol (2004) 0.91
Evaluation of steroid hormone receptor protein expression in intact cells using flow cytometry. Nucl Recept Signal (2007) 0.90
Selective upregulation of scavenger receptors in and around demyelinating areas in multiple sclerosis. J Neuropathol Exp Neurol (2013) 0.90
Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry (2013) 0.90
Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med (2012) 0.90
Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: an "individual patient data" meta-analysis. Depress Anxiety (2014) 0.89
Implementation of a patient education program on multiple sclerosis relapse management. Patient Educ Couns (2011) 0.89